Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2024-03-27 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details repurchases of shares on specific dates, quantities, prices, and confirms compliance with listing rules. The content focuses on share repurchase activity and disclosures required by the Stock Exchange of Hong Kong. There are no financial statements or earnings data, nor is this an announcement of a report publication. The document is a regulatory disclosure about share repurchases, fitting the category of Transaction in Own Shares (POS).
2024-03-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details repurchases of shares on specific dates, quantities, prices, and confirms compliance with listing rules. The content focuses on share repurchase disclosures rather than financial results, management changes, or other report types. This matches the definition of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The document length is over 10,000 characters and contains detailed transactional data, confirming it is the report itself, not just an announcement. Therefore, the correct classification is POS with high confidence.
2024-03-26 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It includes detailed information on repurchases of shares, dates, prices, and confirmations that the repurchases were made in accordance with listing rules. The document is a regulatory disclosure about share repurchases and changes in capital, not a full financial report or earnings release. It fits the description of a Transaction in Own Shares (POS) filing, which reports company buybacks or sales of its own shares. The document length and content confirm it is not a brief announcement but a detailed disclosure form specific to share repurchases.
2024-03-25 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is a Next Day Disclosure Return related to changes in issued share capital and share buybacks by Simcere Pharmaceutical Group Limited. It details a repurchase of shares, including the number of shares repurchased, prices paid, and confirmations of compliance with listing rules. The document is regulatory in nature, reporting a transaction in the company's own shares (share buyback). It is not a full financial report, earnings release, or management discussion, but a formal disclosure of share repurchase activity. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length and content confirm it is a detailed disclosure rather than a brief announcement or certification.
2024-03-22 English
Letter to Non-registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Regulatory Filings Classification · 95% confidence The document is a letter dated March 21, 2024, from Simcere Pharmaceutical Group Limited addressed to non-registered shareholders. It informs shareholders about the company's adoption of electronic dissemination of corporate communications pursuant to the Hong Kong Stock Exchange Listing Rules. The letter explains the types of corporate communications covered (including annual reports, interim reports, notices of meetings, circulars, proxy forms) and provides instructions on how shareholders can receive these communications electronically or in printed form. It also includes a reply form for shareholders to request printed copies. The document does not contain any financial statements, management discussion, voting results, or other substantive report content. Instead, it is an announcement about the method of distribution of corporate communications. The document length is 9108 characters, which is relatively short and consistent with an announcement letter rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about corporate communication dissemination and does not constitute an actual report or financial filing itself.
2024-03-21 English
Letter to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications and Reply Form
Report Publication Announcement Classification · 95% confidence The document is a letter from Simcere Pharmaceutical Group Limited to its shareholders regarding the arrangement for electronic dissemination of corporate communications. It explains the company's adoption of electronic delivery of documents such as annual reports, interim reports, notices of meetings, circulars, and proxy forms. It includes instructions for shareholders to provide their email addresses to receive these communications electronically or to opt for printed copies. The document does not contain any financial data, management discussion, voting results, or regulatory filings itself. It is an announcement about how future reports and communications will be distributed, not the reports themselves. The document length is about 11,782 characters, but it is essentially a notification letter. Therefore, according to the "Menu vs Meal" rule, this is a Report Publication Announcement (RPA) type document, as it announces the method of dissemination of corporate communications rather than being a report or filing itself.
2024-03-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.